Award
National Cancer Institute 5R01CA296410-02
Optimization of an active mutant KRAS peptide vaccine in colorectal cancer
Recipient
Johns Hopkins University, Baltimore, MD
Award Amount
$590,629.00
Ceiling
$590,629.00
Awarded
January 16, 2026
Identifier
5R01CA296410-02
A Phase II clinical trial to optimize a mutant KRAS peptide vaccine combined with immune checkpoint inhibitors for treating colorectal cancer, aiming to improve immune response and clinical outcomes.
Description
This project aims to develop novel immunotherapies targeting KRAS mutations in colorectal cancer, focusing on combination strategies to enhance immune response and clinical outcomes. It involves a Phase II clinical trial studying clinical responses and immunogenicity induced by mKRASvax in combination with immune checkpoint inhibitors and KRAS signaling inhibitors.